Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Merck & Co Inc. revealed on Monday, Nov. 21, that it has acquired Imago BioSciences for $1.35 billion. The New Jersey-based pharmaceutical company is offering $36 per share in cash for the acquisition of the biotech firm, and this amount is said to be equivalent to almost 107% premium to its last closing price.
According to Reuters, this deal between Merck & Co. and Imago BioSciences drug developer is expected to close within the first quarter of 2023. This agreement is said to have opened several markets for the company.
Amid the buyout, Imago BioSciences is currently developing drugs for the treatment of diseases related to born marrow. The company uncovered a small molecule and brought it to phase 2 stage to find stronger evidence that suppressing lysine-specific demethylase 1 (LSD1) lowers the symptoms of myeloproliferative neoplasms or MPNs, which is a group of bone marrow cancers that can potentially develop into acute myeloid leukemia.
If the biotech firm is correct with its findings, bomedemstat will improve the results in the MPNs essential thrombocythemia, myelofibrosis, and polycythemia vera. Merck is interested in this discovery and bought into the idea; thus, it needs to buy Imago BioSciences.
Under the terms of the deal, through a subsidiary, Merck & Co. will set in motion a tender offer to buy all the remaining shares of Imago. Then again, it was noted that the closing of the offer will still be subject to some conditions, such as the expiration of the waiting period. According to the Hart-Scott-Rodino Antitrust Improvements Act, the tender of shares must represent a majority of Imago’s total number of available shares and other standard conditions.
“We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve,” Merck’s president and chief executive officer, Robert M. Davis, said in a press release. “This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology.”
Dr. Hugh Y. Rienhoff, Jr., Imago BioSciences’ founder and CEO, also commented, “This milestone is a testament to more than a decade of pioneering research by Imago scientists and the entire Imago team’s unwavering dedication to improving the lives of patients. this agreement leverages Merck’s industry-leading clinical development expertise to maximize the therapeutic potential of bomedemstat while providing important value for shareholders.”
